Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216938 | 0.79 | MAPK1 (0.50) | KCNN4ALDH1A1TSHRMAPK1TAAR1 | |
| SCHEMBL160204 | 0.79 | TSHR (0.58) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL1001137 | 0.79 | CYP1A2 (0.44) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL28484493 | 0.79 | TSHR (0.58) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL754613 | 0.77 | CYP1A2 (0.42) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL6735941 | 0.77 | MAPK1 (0.48) | KCNN4ALDH1A1TSHRMAPK1TAAR1 | |
| SCHEMBL909523 | 0.77 | KCNN4 (0.41) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL7151184 | 0.77 | KCNN4 (0.41) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL230628 | 0.75 | KCNN4 (0.53) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL1538898 | 0.72 | ALDH1A1 (0.50) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-09-21 | — | — | US | claimed |
| EP-3560937-B1 | METHODS OF PREPARING 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS AND DIAGNOSTIC METHODS THEREWITH | CANCER TARGETED TECH LLC (US) | 2022-12-28 | — | — | EP | claimed |
| WO-2021222783-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2021-11-04 | — | — | WO | claimed |
| CN-108968888-B | Portable neuroendoscopy system suitable for marine naval vessel uses | 中国人民解放军第二军医大学第二附属医院 | 2021-01-29 | — | — | CN | claimed |
| EP-3036227-B1 | PROCESS FOR PREPARING A COMPOUND | GENENTECH INC (US) | 2020-01-08 | — | — | EP | claimed |
| EP-2970345-B1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | CANCER TARGETED TECH LLC (US) | 2019-06-19 | — | — | EP | claimed |
| CN-108968888-A | A kind of portable nerve endoscope system used suitable for marine vessel | 中国人民解放军第二军医大学第二附属医院 | 2018-12-11 | — | — | CN | claimed |
| CN-106083807-B | 4- amino -5- biphenyl -4- base -2- methylol -2- methvl-pentanoic acid compounds and preparation method thereof | 施万生物制药研发IP有限责任公司 | 2018-09-11 | — | — | CN | claimed |
| WO-2018150386-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BORONIC ACID ESTERS | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2018-08-23 | — | — | WO | claimed |
| CN-106083807-A | 4 amino 5 biphenyl 4 base 2 methylol 2 methylvaleric acid compounds and preparation method thereof | 施万生物制药研发IP有限责任公司 | 2016-11-09 | — | — | CN | claimed |
| US-6194509-B1 | VULCANIZABLE FILLER-REINFORCED, ELASTOMER-CONTAINING COMPOSITION COMPRISING ELASTOMER, REINFORCING FILLER, FREE RADICAL CAPPING ADDITIVE, CURE AGENT; PNEUMATIC TIRE COMPRISING A TREAD STOCK MANUFACTURED FROM THE COMPOSITION | BRIDGESTONE CORPORATION (JP) | 2001-02-27 | — | — | US | claimed |
| US-5420149-A | Hypotensive agents and artheriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-30 | — | — | US | claimed |
| EP-0428708-B1 | PROCESS FOR PREPARING A POLYMER HAVING PERFLUOROCYCLOBUTANE RINGS AND POLYMERS CONTAINING PERFLUOROCYCLOBUTANE RINGS | DOW CHEMICAL CO (US) | 1994-10-05 | — | — | EP | claimed |
| US-5352687-A | Hypotensive agents | BAYER AKTIENGESELLSCHAFT (DE) | 1994-10-04 | — | — | US | claimed |
| EP-0428706-B1 | PERFLUOROVINYL COMPOUNDS | DOW CHEMICAL CO (US) | 1994-07-13 | — | — | EP | claimed |
| US-5066746-A | Dielectric Fluids, Lubricants And Plastics | THE DOW CHEMICAL COMPANY (US) | 1991-11-19 | — | — | US | claimed |
| EP-0428708-A1 | PROCESS FOR PREPARING A POLYMER HAVING PERFLUOROCYCLOBUTANE RINGS AND POLYMERS CONTAINING PERFLUOROCYCLOBUTANE RINGS. | DOW CHEMICAL CO (US) | 1991-05-29 | — | — | EP | claimed |
| EP-0428706-A1 | PERFLUOROVINYL COMPOUNDS. | DOW CHEMICAL CO (US) | 1991-05-29 | — | — | EP | claimed |
| WO-1990015043-A2 | PERFLUOROVINYL COMPOUNDS | THE DOW CHEMICAL COMPANY (US) | 1990-12-13 | — | — | WO | claimed |
| WO-1990015082-A1 | PROCESS FOR PREPARING A POLYMER HAVING PERFLUOROCYCLOBUTANE RINGS AND POLYMERS CONTAINING PERFLUOROCYCLOBUTANE RINGS | THE DOW CHEMICAL COMPANY (US) | 1990-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | TM9SF4, TM9SF2, TM9SF3 | KCNN4 3800/4885ALDH1A1 2644/4885TSHR 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.